RPID Shareholder Alert: ADEMI LLP Investigates Whether Buyout Fairly Values Rapid Micro Biosystems, Inc.
Globe Newswire•16/11/2026•12:08 ET
1
Key Highlights
- ➤Rapid Micro Biosystems shareholders will receive $0.75 per share in Merck’s all-cash buyout
- ➤Ademi LLP is investigating whether the purchase price fairly reflects RPID’s value
- ➤Insider change-of-control benefits are under investigation
- ➤Deal restrictions and a significant termination penalty may deter superior offers
RPID shareholders will receive just $0.75 per share in an all-cash transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
MILWAUKEE, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating whether the proposed acquisition of Rapid Micro Biosystems (NASDAQ: RPID) by Merck, provides fair value to Rapid Micro Biosystems’ public shareholders and whether Rapid Micro Biosystems’ Board adequately protected shareholder interests in negotiating and approving the transaction.
Get started
Create a free account to read the full story.
